

28^{ÈME}
CONGRÈS
CNCH
PRÉSENTIEL & DIGITAL

CNCH 2022 Tous droits réservés Toute reproduction même partielle interdite



CONGRÈS ESC 2022

Les recommandations ESC 2022 sur la cardio-oncologie

Dr JAGU Annabelle
Service de cardiologie
Groupe hospitalier Paris Saint Joseph



GROUPE
HOSPITALIER
PARIS
SAINT-JOSEPH



Déclaration de liens d'intérêt potentiels

Pas de lien d'intérêt potentiel à déclarer

CNCH 2022 Tous droits réservés Toute



ESC CPG POSITION PAPER

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

Recommandations cardio-oncologiques ESC 2022 :

- 1ères recommandations européennes
- Riches : 133 pages
- Recommandations communes : cardiologie / oncologie / hématologie / radiologie

Dr JAGU Annabelle
Cardiologue : Hôpital Saint Joseph



ESC

European Society of Cardiology

European Heart Journal (2022) 00, 1–133
<https://doi.org/10.1093/eurheartj/ehac344>



ESC GUIDELINES

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)

Authors/Task Force Members: Alexander R. Lyon^{*†} (Chairperson) (United Kingdom), Teresa López-Fernández^{*†} (Chairperson) (Spain), Liam S. Couch (Task

Lyon, Alexander R et al. "2022 ESC Guidelines on cardio-oncology" *European heart journal* vol. 43,41 (2022): 4229-4361. doi:10.1093/eurheartj/ehac244

production même partielle interdite

bits réservés

Toute repro

repro

6 grandes parties

1. Définitions
2. Baseline évaluation **NEW**
3. Monitoring
4. Toxicités
5. Survivants **NEW**
6. Populations particulières **NEW**

1. Principles	4	4.1.2.1. Human epidermal receptor tyrosine kinase inhibitor	14
2. Introduction	13	4.1.2.2. Human epidermal receptor tyrosine kinase inhibitor: safety	14
2.1. Current and envisioned clinical trials of patients with cancer	13	4.1.3. Kinase inhibitors: development, initiation, associated toxicity, and time-to-treatment failure	16
2.2. Role of cardio-oncology services	13	4.1.4. Kinase inhibitors: toxicity management	17
2.3. General principles of cardio-oncology	11	4.1.5. Kinase inhibitors: toxicity management: T cell and tumour-infiltrating lymphocytes, thymus, and heart dysfunction	17
3. Cancer therapy-related cardiovascular toxicity definitions	11	4.1.5.1. Heart failure during hematopoietic stem cell transplantation	17
4. Cardiovascular toxicity risk stratification before anticancer therapy	15	4.1.5.2. Heart failure during hematopoietic stem cell transplantation	17
4.1. General approach to cardiovascular toxicity risk in patients with cancer	15	4.1.6. Takotsubo syndrome and cancer	17
4.2. History and clinical examination	21	4.2. Coronary artery disease	17
4.3. Medical diagnosis	21	4.2.1. Acute coronary syndromes	17
4.4. Cardiac serum biomarkers	21	4.2.2. Chronic coronary syndromes	17
4.5. Cardiovascular imaging	24	4.3. Valvular heart disease	18
4.6. Cardiovascular physical assessment	25	4.4. Cardiac arrhythmias	18
4.7. Cardiovascular risk evaluation before cancer therapy	26	4.4.1. Atrial fibrillation	18
4.8. Genetic testing	26	4.4.2. Long QT interval and ventricular arrhythmias	20
5. Prevention and monitoring of cardiovascular toxicity during cancer therapy	26	4.4.3. Proarrhythmias	21
5.1. General principles	26	4.5. Atrial septal aneurysm	22
5.2. Primary prevention strategies	28	4.6. Thrombotic and thromboembolic events	22
5.2.1. Primary prevention strategies: cancer therapy-related cardiovascular toxicity during antiarrhythmic therapy	28	4.6.1. Venous thromboembolism	22
5.2.2. Primary prevention strategies: cancer therapy-related cardiovascular toxicity during immunotherapy	28	4.6.2. Arterial thromboembolism	24
5.2.3. Primary prevention strategies: cancer therapy-related cardiovascular toxicity during targeted therapy	28	4.6.3. Anticoagulation therapy	27
5.3. Secondary prevention strategies	29	4.7. Bleeding complications	28
5.4. Cardiovascular surveillance during cancer therapy	29	4.7.1. High-risk patients	28
5.4.1. Cardiac serum biomarkers	29	4.7.2. Antiplatelet therapy	28
5.4.2. Cardiac imaging	29	4.7.3. Management of bleeding	28
5.4.3. Cancer therapy-related cardiovascular toxicity monitoring protocols	31	4.8. Pericardial artery disease	28
5.4.3.1. Antiarrhythmic therapy	31	4.9. Pulmonary hypertension	28
5.4.3.2. HF/CO2 retained therapy	31	4.9.1. Pericarditis	28
5.4.3.3. Haemostatic drugs	32	4.9.2. Pericardial disease	28
5.4.3.4. Inhibitor of endothelial growth factor inhibitors	33	4.9.3. Pericardial disease	28
5.4.3.5. Multitargeted kinase inhibitors targeting EGFR/HER	33	5. Drug therapy: cardiovascular assessment	31
5.4.3.6. Inhibitor of endothelial growth factor inhibitors	33	5.1. Cardiovascular evaluation during the first year after anticancer therapy	31
5.4.3.7. Multitargeted kinase inhibitors targeting EGFR/HER	33	5.2. Which cardiovascular toxicity requires monitoring or surveillance in the first year after cancer treatment?	31
5.4.3.8. Inhibitor of endothelial growth factor inhibitors	33	5.3. Management of cancer therapy-related cardiovascular toxicity at the end-of-therapy assessment	32
5.4.3.9. Specific antineoplastic therapies and integrin-inhibited extracellular signal-regulated kinase inhibitor treatment	35	5.4. Cardiovascular toxicity monitoring and follow-up during the end-of-therapy assessment	32
5.4.3.10. Kinase inhibitors	35	5.5. The role of cardiac surveillance	32
5.4.3.11. Kinase inhibitors	35	6. Long-term follow-up and chronic cardiovascular complications in cancer survivors	34
5.4.3.12. Kinase inhibitors	35	6.1. Cancer survivors	34
5.4.3.13. Kinase inhibitors	35	6.1.1. Adult survivors of childhood and adolescent cancer	34
5.4.3.14. Kinase inhibitors	35	6.1.2. Adult cancer survivors	35
5.4.3.15. Kinase inhibitors	35	6.2. Pericardial dysfunction and heart failure	35
5.4.3.16. Kinase inhibitors	35	6.3. Coronary artery disease	36
5.4.3.17. Kinase inhibitors	35	6.4. Valvular heart disease	36
5.4.3.18. Kinase inhibitors	35	6.5. Pericardial artery disease and stroke	36
5.4.3.19. Kinase inhibitors	35	6.6. Pericardial tamponade	36
5.4.3.20. Kinase inhibitors	35	6.7. Arrhythmias and cardiac conduction disease	36
6. Diagnosis and management of cardiovascular toxicity during anticancer therapy	34		






L'essence de la cardio-oncologie

- « **Avant** » : Prise en charge des FDRCV
- « **Pendant** » : Détection des toxicités
- « **Après** » : Surveillance des survivants


Surveillance tout au long du parcours



Score de risque = essentiel ++

Stratification du risque = *Score HFA-ICOS*

- Existence d'une **cardiopathie**
- Symptômes CV
- **Biomarqueurs**
- **FEVG**




Evaluation selon le score de risque

Patients à **haut risque** :

- Surveillance **renforcée**

Patients à **faible risque**


- Surveillance **allégée**



Prévention de la cardio toxicité

Patients à *haut risque* et/ou en *prévention secondaire* :

- **Maintien** cardioprotection : IEC/BB ...
- **Minimiser** médicament cardiotoxique
- **Optimiser** FDRCV



ESC pockets guidelines

Sélectionner *cardio-onco pockets guidelines*

Questionnaire classé *par molécule*


- Ex : Anthracycline Chemotherapy Baseline Risk



ESC pockets guidelines

Stratification du *risque* basé sur :

- Existence d'une **cardiopathie**
- Symptômes CV
- **Biomarqueurs**
- **FEVG**



**Anthracycline
Chemotherapy. ...**

Previous Cardiovascular Disease

Heart failure or cardiomyopathy	<input type="button" value="Yes"/>	<input checked="" type="button" value="No"/>
Severe valvular heart disease	<input checked="" type="button" value="Yes"/>	<input type="button" value="No"/>
Myocardial infarction or previous coronary revascularisation (PCI or CABG)	<input type="button" value="Yes"/>	<input checked="" type="button" value="No"/>
Stable angina	<input checked="" type="button" value="Yes"/>	<input type="button" value="No"/>
Baseline LVEF <50%	<input type="button" value="Yes"/>	<input checked="" type="button" value="No"/>
Borderline LVEF 50-54%	<input type="button" value="Yes"/>	<input checked="" type="button" value="No"/>

Cardiac Biomarkers (Where Available)

Home TOC Search My Library History

Points clés recommandations cardio oncologie ESC 2022

- **Score de risque = pierre angulaire** de ces recommandations
- **Optimiser** au mieux les patients sur le plan des FDRCV
- Surveillance **renforcée** en cas de très haut risque et **allégée** en cas de bas risque
- Vrai chapitre sur les **survivants** = population à surveiller
- Cardio-oncologue = **facilitateur** du traitement oncologique

28^{ÈME}
CONGRÈS
CNCH
PRÉSENTIEL & DIGITAL
CNCH 2022 Tous droits réservés - Toute reproduction même partielle interdite



Suivez le CNCH sur le Social Média !

#CNCHcongres



@CNCHcollege



@CNCHcollege

Si vous voulez devenir Ambassadeur social media CNCH adressez-nous un email à cnch@sfcardio.fr